Clinical Trial Update: CAIX PET/CT for Residual or Recurrent Post-ablative ccRCC [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating CAIX-targeted PET/CT imaging for residual or recurrent post-ablative clear cell renal cell carcinoma; the study is not yet rec…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clear Cell Renal Cell Carcinoma

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Clear Cell Renal Cell Carcinoma (ccRCC), ccRCC | Phase 2 | Status: NOT_YET_RECRUITING